Canada markets closed
  • S&P/TSX

    20,463.42
    +60.76 (+0.30%)
     
  • S&P 500

    4,443.11
    -12.37 (-0.28%)
     
  • DOW

    34,869.37
    +71.37 (+0.21%)
     
  • CAD/USD

    0.7920
    +0.0016 (+0.20%)
     
  • CRUDE OIL

    75.42
    -0.03 (-0.04%)
     
  • BTC-CAD

    54,415.88
    -775.89 (-1.41%)
     
  • CMC Crypto 200

    1,062.43
    -39.09 (-3.55%)
     
  • GOLD FUTURES

    1,750.80
    -1.20 (-0.07%)
     
  • RUSSELL 2000

    2,281.00
    +32.93 (+1.46%)
     
  • 10-Yr Bond

    1.4840
    +0.0240 (+1.64%)
     
  • NASDAQ futures

    15,174.50
    -20.25 (-0.13%)
     
  • VOLATILITY

    18.76
    +1.01 (+5.69%)
     
  • FTSE

    7,063.40
    +11.92 (+0.17%)
     
  • NIKKEI 225

    30,240.06
    -8.75 (-0.03%)
     
  • CAD/EUR

    0.6769
    +0.0029 (+0.43%)
     

Black Diamond Therapeutics to Present at Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass. and NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the following upcoming investor conferences:

  • The 2021 Wedbush PacGrow Healthcare Conference. Dr. Epstein will be featured in a Targeted Oncology panel on Wednesday, August 11, 2021 at 10:20 AM ET. The session will be available via live webcast to conference attendees.

  • The Canaccord Genuity 41st Annual Growth Conference. The presentation will take place on Thursday, August 12, 2021 at 1:00 PM ET.

A live webcast of the Canaccord Genuity presentation can be accessed by visiting the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the presentation will also be available and archived on the site for three weeks.

About Black Diamond

Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, MasterKey therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform and drug discovery engine, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy that targets a specific family of mutations, termed a MasterKey therapy. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts
For Investors:
Natalie Wildenradt
investors@bdtx.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtx.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting